Saturday 17 October 2026
Export DRMA’s income statement to Excel — free account
Dermata Therapeutics, Inc.
DRMA Healthcare Biotechnology
In the quarter to June 2026, EPS grew 55.4% and free cash flow grew 9.99%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
0.86
0.05
−5.49%
Follow DRMA
Target Price Range
Analyst price targets
Free accountTen years at a glance
| Group | Line | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | Trend | 2026e | 2027e | 2028e |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Price, $ | |||||||||||||||
| Price, $ | Low | — | — | — | — | — | 3,648.00 | 388.80 | 80.40 | 10.00 | 1.58 |
Analyst estimates 2026–2028 Powerpack |
|||
| High | — | — | — | — | — | 16,680.00 | 5,880.00 | 924.00 | 133.50 | 23.70 | |||||
| People | |||||||||||||||
| People | Employees | — | — | — | — | 7 | 8 | 8 | 8 | 8 | 9 | ||||
| Revenue/emp, $m | — | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Income, $m | |||||||||||||||
| Income, $m | Revenue | — | — | — | — | — | — | — | — | — | — | ||||
| Gross margin, % | — | — | — | 0.00 | 0.00 | — | — | — | — | — | |||||
| EBT | — | — | — | (5) | (3) | (8) | (10) | (8) | (12) | (8) | |||||
| EBT margin, % | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Net income | — | 0 | — | (5) | (3) | (8) | (10) | (8) | (12) | (8) | |||||
| Depreciation | — | — | — | 0 | 0 | 0 | — | — | — | — | |||||
| Per share, $ | |||||||||||||||
| Per share, $ | Revenue | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | ||||
| Earnings | — | — | — | (5,926.50) | (4,062.67) | (5,829.08) | (2,086.96) | (400.30) | (80.30) | (8.16) | |||||
| Cash flow | — | — | — | (4,902.87) | (5,035.62) | (3,163.00) | (1,920.48) | (328.66) | (72.96) | (8.38) | |||||
| Capex | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| Free cash flow | — | — | — | (4,902.87) | (5,035.62) | (3,163.00) | (1,920.48) | (328.66) | (72.96) | (8.38) | |||||
| Book value | — | — | — | (262.75) | (3,972.37) | 5,615.06 | 1,309.11 | 325.90 | 10.20 | 6.72 | |||||
| Shares, m | — | — | — | 0 | 0 | 0 | 0 | 0 | 0 | 1 | |||||
| Valuation, × | |||||||||||||||
| Valuation, × | P/E | — | — | — | — | — | — | — | — | — | — | ||||
| P/S | — | — | — | — | — | — | — | — | — | — | |||||
| P/B | — | — | — | — | — | — | — | — | — | — | |||||
| EV/Sales | — | — | — | — | — | — | — | — | — | — | |||||
| EV/FCF | — | — | — | — | — | — | — | — | — | — | |||||
| Cash, $m | |||||||||||||||
| Cash, $m | Operating cash flow | — | — | — | (4) | (4) | (6) | (9) | (6) | (11) | (8) | ||||
| Capex | — | — | — | — | — | — | — | — | — | — | |||||
| Free cash flow | — | — | — | (4) | (4) | (6) | (9) | (6) | (11) | (8) | |||||
| Balance, $m | |||||||||||||||
| Balance, $m | Working capital | — | — | — | 0 | (3) | 10 | 6 | 6 | 2 | 6 | ||||
| Total debt | — | — | — | 1 | 4 | — | — | — | — | — | |||||
| Net debt | — | — | — | (1) | 3 | (11) | (6) | (7) | (3) | (8) | |||||
| Shareholders’ equity | — | — | — | 0 | (3) | 10 | 6 | 6 | 2 | 6 | |||||
| Returns, % | |||||||||||||||
| Returns, % | ROA | — | — | — | (457.10) | (242.32) | (171.14) | (103.52) | (104.46) | (213.46) | (132.63) | ||||
| ROIC | — | — | — | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | |||||
| ROE | — | — | — | 19.58 | 13.42 | 134.00 | (119.18) | (125.96) | (310.44) | (194.20) | |||||
Negative figures in brackets.
Charts ten years each
Dermata Therapeutics, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier
| Company | Market cap | P/E | Fwd P/E | Revenue growth (Q) | EPS growth (Q) | FCF growth (Q) | Gross margin (Q) | EBIT margin (Q) | Compare |
|---|---|---|---|---|---|---|---|---|---|
| LGVN Longeveron Inc. | $4.8M | — (loss-making) | — (loss-making) | −9.18% (below 0%: shrinking) | n/m | −49.12% (below 0%: shrinking) | 63.41% | (2,150.17%) | Compare |
| XBIO Xenetic Biosciences, Inc. | $4.7M | — (loss-making) | — (loss-making) | +11.99% (above 0%: growing) | n/m | −128.11% (below 0%: shrinking) | 100.00% | (147.09%) | Compare |
| PCSA Heatwurx Inc. | $4.7M | 1.6× | — | −64.29% (below 0%: shrinking) | n/m | +20.29% (above 0%: growing) | 0.00% | 0.00% | Compare |
| DRMA Dermata Therapeutics, Inc. | $4.5M | — (loss-making) | — | — | n/m | +9.99% (above 0%: growing) | 0.00% | 0.00% | |
| ENLV Enlivex Ltd. | $4.5M | 0.0× | — | — | n/m | +35.94% (above 0%: growing) | 0.00% | 0.00% | Compare |
| NCNA NuCana PLC Sponsored ADR | $4.4M | — (loss-making) | — | — | n/m | +55.66% (above 0%: growing) | 0.00% | 0.00% | Compare |
| ADTX Aditxt, Inc. | $4.4M | — (loss-making) | — | +1,120.00% (above 0%: growing) | n/m | +60.82% (above 0%: growing) | 23.77% | (35,753.28%) | Compare |
| AZTR Azitra, Inc. | $4.3M | 1.0× | — (loss-making) | −93.38% (below 0%: shrinking) | n/m | −19.55% (below 0%: shrinking) | 100.00% | 0.00% | Compare |
| LIMN Liminatus Pharma Inc. | $4.3M | — (loss-making) | — | — | n/m | +89.00% (above 0%: growing) | — | 0.00% | Compare |
| Median of peers | $4.4M | 1.0× | — | −9.18% | — | +28.12% | 23.77% | 0.00% |
Dermata Therapeutics, Inc. (DRMA) key facts
- Dermata Therapeutics, Inc. (DRMA) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
- As of October 16, 2026, DRMA traded at $0.86, a market capitalization of $4.5 million.
- Return on equity was −194.2% and debt-to-equity 0.00.